AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
MaxCyte Cancels AIM Market Trading, Shares Remain Listed on Nasdaq
ByAinvest
Wednesday, Jun 25, 2025 8:37 pm ET1min read
MaxCyte has announced the cancellation of its common stock trading on the AIM market of the London Stock Exchange, effective June 26, 2025. The company's shares will continue to trade on the Nasdaq Global Select Market under the ticker symbol MXCT. The most recent analyst rating on MXCT stock is a Buy with a $7.00 price target.
MaxCyte, Inc. (NASDAQ: MXCT) has announced the cancellation of its common stock trading on the AIM market of the London Stock Exchange, effective June 26, 2025. The company's shares will continue to trade on the Nasdaq Global Select Market under the ticker symbol MXCT. The most recent analyst rating on MXCT stock is a Buy with a $7.00 price target.The delisting from the AIM market is expected to take effect at 7:00 a.m. U.K. time on Thursday, with the last day of trading on AIM being Wednesday. The stock has seen significant pressure recently, declining over 46% in the past six months and trading near its 52-week low of $2.01 [1].
MaxCyte's first-quarter 2025 earnings report revealed a revenue of $10.4 million, which exceeded the forecasted $9.05 million. The company’s earnings per share (EPS) were -$0.10, slightly better than the anticipated -$0.11. Despite the positive earnings surprise, BTIG analyst Mark Massaro adjusted the price target for MaxCyte to $5.00 from $6.00, while maintaining a Buy rating on the stock. This adjustment reflects current macroeconomic challenges and funding uncertainties within the biopharmaceutical industry [1].
MaxCyte shareholders have approved an amendment to the company’s 2022 Equity Incentive Plan, increasing the authorized shares by 2,950,000, and supported the delisting from the AIM market of the London Stock Exchange [1]. The company continues to focus on expanding its presence in the cell and gene therapy market, leveraging its premier technology in non-viral gene editing [1].
The delisting from the AIM market will also impact the FTSE UK Index Series. The FTSE AIM 100 Index and the FTSE AIM All-Share Index will be affected, with the changes taking effect on June 26, 2025 [2].
References:
[1] https://uk.investing.com/news/sec-filings/maxcyte-to-delist-shares-from-london-aim-maintains-nasdaq-listing-93CH-4147233
[2] https://www.tradingview.com/news/reuters.com,2025-06-23:newsml_RSW0278Oa:0-reg-ftse-russell-maxcyte-inc-maxcyte/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet